VectorY Announces Participation in Scientific Conferences in October 2022

AMSTERDAM–(BUSINESS WIRE)–VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neuro-degenerative and muscular disorders through vectorized antibodies, today announces participation in three upcoming conferences.

5th Annual ALS Research Symposium (ALS ONE), 6-7 & 11 October, virtually

Presentation title: Reduction of oxidized phospholipids or misfolded protein aggregates by AAV-VecTabs in an Amyotrophic Lateral Sclerosis pre-clinical models

Presenter: Pavlina Konstantinova, Chief Scientific Officer

Time and date: October 7, 14:05 ET

European Society of Gene & Cell Therapy (ESGCT) Annual Congress, 11-14 October, Edinburgh

Poster title: VecTrons: Targeting misfolded proteins in neurodegenerative diseases

Presenter: Menno Spits, Scientist

Poster number: P251

Time and date: October 12, Poster Session 1,19:30-21:00 BST

Poster title: Generation and characterization of stable recombinant baculoviruses for large-scale production of rAAV

Presenter: Hilde van Tongeren, Head of Vector Generation

Poster number: P293

Time and date: October 12, Poster Session 1, 19:30-21:00 BST

Poster title: VecTabs® and advanced human in-vitro models: targeting TDP-43 aggregates and oxidized phosphocholines in Amyotrophic lateral sclerosis

Presenter: Andreia Duarte, Scientist

Poster number: P353

Time and date: October 12, Poster Session 1, 19:30-21:00 BST

Poster title: Next generation rAAV capsids show enhanced transduction efficiency in 2D and 3D human cellular models for neurodegenerative diseases

Presenter: Carmen Gallego, Scientist, Vector Technologies

Poster number: P056

Time and date: October 13, Poster Session 2, 17:30-19:15 BST

2022 Cell & Gene Meeting on the Mesa, 11-13 October, Carlsbad, CA

Presentation title: Precision targeted gene therapies for CNS and neuromuscular disease

Presenter: Barbara Sanders, Chief Technology Officer

Time and date: October 13, 11:45 PT

To meet the VectorY team at any of these meetings, please contact


Notes to Editors

About VectorY

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative and muscular diseases with high unmet medical need such as amyotrophic lateral sclerosis (ALS) and Huntington’s disease.

VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative and muscular diseases, VectorY’s synergistic technologies may be applied across a wide range of indications.

VectoryY was founded in October 2020 and is based on the Amsterdam Science Park.

For more information, see


VectorY B.V.
Sariette Witte, Head of Communications

Tel: +31 (20) 226 8020

Instinctif Partners (media enquiries)
Melanie Toyne-Sewell /Giulia Lasagni/ Manisha Kuttetira

Tel: +44 20 7457 2020

Thank you for donating to

We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.

Make a donation